Travere Therapeutics (TVTX) Operating Expenses (2016 - 2025)
Historic Operating Expenses for Travere Therapeutics (TVTX) over the last 17 years, with Q3 2025 value amounting to $139.9 million.
- Travere Therapeutics' Operating Expenses rose 1754.01% to $139.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $527.0 million, marking a year-over-year decrease of 602.97%. This contributed to the annual value of $557.0 million for FY2024, which is 442.95% up from last year.
- According to the latest figures from Q3 2025, Travere Therapeutics' Operating Expenses is $139.9 million, which was up 1754.01% from $127.1 million recorded in Q2 2025.
- Travere Therapeutics' Operating Expenses' 5-year high stood at $180.6 million during Q1 2024, with a 5-year trough of $46.4 million in Q4 2021.
- Its 5-year average for Operating Expenses is $118.0 million, with a median of $121.8 million in 2024.
- Its Operating Expenses has fluctuated over the past 5 years, first tumbled by 7260.42% in 2021, then skyrocketed by 14984.61% in 2022.
- Over the past 5 years, Travere Therapeutics' Operating Expenses (Quarter) stood at $46.4 million in 2021, then soared by 149.85% to $116.0 million in 2022, then rose by 20.04% to $139.3 million in 2023, then dropped by 2.71% to $135.5 million in 2024, then grew by 3.25% to $139.9 million in 2025.
- Its Operating Expenses stands at $139.9 million for Q3 2025, versus $127.1 million for Q2 2025 and $124.4 million for Q1 2025.